Crossmark

Immunostimulatory gene therapy targeting CD40, 4-1BB and IL-2R activates DCs and stimulates antigen-specific T-cell and NK-cell responses in melanoma models

Crossref DOI link: https://doi.org/10.1186/s12967-023-04374-2

Published Online: 2023-07-27

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Wenthe, Jessica https://orcid.org/0000-0003-4385-7568
Eriksson, Emma

Hellström, Ann-Charlotte

Moreno, Rafael

Ullenhag, Gustav

Alemany, Ramon

Lövgren, Tanja

Loskog, Angelica
Funding

Funding for this research was provided by:

Cancerfonden (20 0756 PjF)

Barncancerfonden (PR2021-0061)

Vetenskapsrådet (2019-01721)

Lokon Pharma AB

Uppsala University
License Information

Text and Data Mining valid from 2023-07-27

Version of Record valid from 2023-07-27
More Information

Article History

Received: 11 May 2023

Accepted: 19 July 2023

First Online: 27 July 2023

Declarations

:

: Animal experiments were approved by the local animal ethical review board in Uppsala, Sweden (DNr 5.8.18-08932/2019).

: Not applicable.

: AL is the CEO and board member of Lokon Pharma AB holding a patent related to the work (WO2015155174A1). She also holds a research grant from Lokon Pharma AB. AL is a scientific advisor and alternate board member of NEXTTOBE AB. She is the founder of Lynxalo AB. JW and EE are employed by Lokon Pharma AB. The remaining authors declare no financial competing interest.

Document is current

Any future updates will be listed below